Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Phase 2 Terminated 3 enrolled Masonic Cancer Center, University of Minnesota

NaSingle-groupOpen-labelTreatment

Summary

This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.

Timeline

Start: 2017-02-16
Primary completion: 2019-06-20
Completion: 2019-06-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Treg	Unknown	—	—
Background	Allopurinol	Small molecule	—	—
Background	Cyclophosphamide	Other / unclassified	50 mg/kg	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous
Background	Mycophenolate Mofetil	Small molecule	3 g	Intravenous
Background	Sirolimus	Small molecule	4 mg	Oral

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Summary

Timeline

Drugs

Indications